Finance

Lists
Why is CLYM up 16,01%?
Dive Deeper
CLYM:NASDAQ
Climb Bio Inc
10,29 $
+16,01%
(+1,42) 1D
10,34 $
+0,49% (+0,050)
After hours
Closed: 6 նոյ, 16:00:01 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CLYM...
Open
9,05 $
High
10,33 $
Low
8,84 $
Mkt. cap
591,02 մլն
Avg. vol.
1,17 մլն
Volume
1,14 մլն
52-wk high
18,33 $
52-wk low
1,64 $
EPS
-0,82 $
Beta
0,04
Shares outstanding
57,44 մլն
No. of employees
29
Open
9,05 $
High
10,33 $
Low
8,84 $
Mkt. cap
591,02 մլն
Avg. vol.
1,17 մլն
Volume
1,14 մլն
52-wk high
18,33 $
52-wk low
1,64 $
EPS
-0,82 $
Beta
0,04
Shares outstanding
57,44 մլն
No. of employees
29
News stories
From web sources and news partners
About Climb Bio Inc
CEO-
Employees29
Founded2018
HeadquartersWellesley Hills, Մասսաչուսեթս, Միացյալ Նահանգներ
SectorHealth Care
Industry-
Analyst ratings
Based on 12 analysts giving stock ratings to CLYM in the past 3 months
Strong buy
Buy
12
Hold
0
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for CLYM in the last 3 months.
Highest
Current 10,29 $
40,00 $ (+288,73%)
Average
29,09 $ (+182,70%)
Lowest
23,00 $ (+123,52%)
Analyst
Recommendation
Action
Price target
Projected
Date
Danielle Brill
Truist Financial
Buy
Maintained
25,00 $
+143%
11/06/2026
Laura Chico
Wedbush
Buy
Maintained
27,00 $
+162,4%
11/06/2026
Unknown Analyst
Oppenheimer
Buy
Reiterated
25,00 $
+143%
11/06/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
35,00 $
+240,1%
11/05/2026
Julian Harrison
BTIG
Buy
Maintained
32,00 $
+211%
11/04/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
40,00 $
+288,7%
10/30/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
30,00 $
+191,5%
10/27/2026
David Hoang
Deutsche Bank
Buy
Initiated
28,00 $
+172,1%
10/20/2026
Nevin Varghese
RBC Capital
Buy
Maintained
23,00 $
+123,5%
10/13/2026
Mayank Mamtani
B. Riley Securities
Buy
Maintained
30,00 $
+191,5%
09/04/2026
Brian Skorney
Robert W. Baird
Buy
Maintained
25,00 $
+143%
09/03/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
09/03/2026
Leland Gershell
Oppenheimer
Buy
Maintained
18,00 $
+74,9%
08/07/2026
Christopher Raymond
Raymond James
Buy
Maintained
-
-
06/24/2026
Thomas Smith
Leerink Partners
Buy
Reiterated
-
-
06/12/2026
Colleen M. Kusy
Robert W. Baird
Buy
Maintained
21,00 $
+104,1%
05/06/2026
Geulah Livshits
Chardan Capital
Buy
Initiated
22,00 $
+113,8%
05/05/2026
Joseph Catanzaro
Mizuho Securities
Buy
Initiated
18,00 $
+74,9%
04/15/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
2026 թ. սեպ
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
13,74 մլն
9,37 մլն
9,71 մլն
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,56 մլն
5,84 մլն
5,64 մլն
-
Operating expense
19,30 մլն
15,21 մլն
15,36 մլն
-
Total operating expenses
19,30 մլն
15,21 մլն
15,36 մլն
-
Operating income
-19,30 մլն
-15,21 մլն
-15,36 մլն
-
Other non operating income
-
-
-
-
EBT including unusual items
-17,52 մլն
-13,72 մլն
-13,50 մլն
-
EBT excluding unusual items
-17,52 մլն
-13,72 մլն
-13,50 մլն
-
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-17,52 մլն
-13,72 մլն
-13,50 մլն
-
Net profit margin
-
-
-
-
Earnings per share
-0,26
-0,20
-0,18
-0,18
Interest and investment income
1,83 մլն
1,51 մլն
1,86 մլն
-
Interest expense
-
-
-
-
Net interest expenses
1,83 մլն
1,51 մլն
1,86 մլն
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-19,27 մլն
-15,17 մլն
-15,33 մլն
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google Apps